Tryg A/S - weekly report on share buy backs In the period

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Tryg A/S - weekly report on share buy backs

In the period from 3 to 7 October 2016 , Tryg purchased own shares for an amount of DKK 35m as part of the share buy back programme of DKK 1,000m initiated on 6 April 2016. The programme will run until 30 December 2016. Since the share buy back programme was initiated, the total number of repurchased s hares is 5,634,464 at a total amount of DKK 717m corresponding to 72% of the programme. Last week the following transactions have been made:

  Number of shares Average purchase price Transaction value (DKK)
3 October 2016 31,250 134.73 4,210,169
4 October 2016 50,000 138.09 6,904,280
5 October 2016 50,000 137.73 6,886,580
6 October 2016 67,358 139.36 9,387,294
7 October 2016 55,775 139.34 7,771,783
Accumulated   254,383 138.22 35,160,106

See all transactions on each trading day in the attachment. The share buy back programme is arranged in compliance with the EU Commission Regulation no. 1052/2016 of 8 March 2016. With the transactions stated above, Tryg owns a total of 5,787,369 shares, corresponding to 2.0 % of the total number of shares of 282,541,204. Adjusted for own shares, the number of shares is 276,753,835. Additional information For further information visit tryg.com or contact Investor Relations;

  • Investor Relations Officer Gianandrea Roberti on +45 20 18 82 67 or gianandrea.roberti@tryg.dk
  • Investor Relations Manager Peter Brondt on +45 22 75 89 04 or peter.brondt@tryg.dk

Tryg is the second-largest insurance company in the Nordic region with activities in Denmark, Norway and Sweden. Tryg provides peace of mind and value for 2.7 million customers on a daily basis. Tryg is listed on Nasdaq Copenhagen and 60% of the shares are held by TryghedsGruppen smba. TryghedsGruppen, annually, contributes around DKK 500m to peace of mind purposes via TrygFonden.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Current Market Sentiment on HealthEquity Shares: A Closer Look

Updated Category News Views 113

Understanding HealthEquity's Short Interest Dynamics HealthEquity Inc (NYSE: HQY) has seen a significant decrease in its short percent of float, which recently dropped by 11.68%. As of the last report, the company had approximately 5.26 million shares sold short, representing 7.03% of its regular shares available for trading. This situation also highlights an average...

Continue Reading
Investors Update: Class Action Against Bumble Inc. Soon

Updated Category News Views 104

Update on Class Action Lawsuit Against Bumble Inc. (BMBL) The Law Offices of Frank R. Cruz are reminding investors about an upcoming significant deadline concerning a class action lawsuit against Bumble Inc. This lawsuit affects investors who acquired BMBL securities during the designated Class Period. Understanding the Class Action Lawsuit The class action was initiated...

Continue Reading
Analysis of Williams-Sonoma's Recent Surge and Current Changes

Updated Category News Views 293

Understanding Williams-Sonoma's Recent Stock Movements This week has seen an impressive rise of nearly 30% in shares of Williams-Sonoma, Inc. (NYSE: WSM), but recent trading indicates a slight pullback. Investors are reacting to two key factors: the natural tendency to take profits and the decision of some buyers to exit losing positions as market conditions evolve. The...

Continue Reading
Understanding the Arconic Corporation Class Action Update

Updated Category News Views 139

Overview of the Class Action Lawsuit Against Arconic Corporation Levi & Korsinsky, LLP has recently announced a class action regarding Arconic Corporation (ARNC). This situation affects investors who may have been impacted by alleged securities fraud. The firm aims to represent those who traded Arconic shares during a specified period and seeks to recover losses resulting...

Continue Reading
Cambrex Partners with Lilly to Enhance Biotech Innovations

Updated Category News Views 220

Cambrex's Strategic Collaboration with Eli Lilly Cambrex, a key player in the global contract development and manufacturing organization (CDMO) sector, has announced an exciting new partnership with Eli Lilly and Company to enhance support for biotech collaborators. Through this agreement, Cambrex aims to provide accelerated access to essential clinical development...

Continue Reading